Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Vanguard Total International Stock Index Fund ETF trades at $84.46. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | VXUS | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Sector/Thematic |
52-Week High | $30.81 | $87.06 |
52-Week Low | $16.87 | $68.24 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
VXUS trades at $85.34, up 0.52% on the day, with a neutral technical signal and bullish moving averages. The ETF offers broad international equity exposure across 8,738 stocks, providing diversification benefits. Recent news highlights its role in portfolio construction amid high U.S. valuations, with Vanguard surpassing iShares as the largest ETF provider in June 2026.
The outlook for VXUS is supported by its low-cost structure and global diversification, appealing for long-term investors seeking non-U.S. exposure. Risks include currency fluctuations and emerging market volatility. Analyst sentiment is neutral, with the ETF positioned as a core holding for balanced portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
